Innoviva Bolsters Its Infectious Disease, Hospital Portfolio With La Jolla Deal

  • Innoviva Inc INVA has agreed to acquire La Jolla Pharmaceutical Company LJPC for $5.95 per share, representing a premium of approximately 70% to the 30-day volume-weighted average price.
  • Innoviva will also pay an incremental $0.28 per share for additional cash proceeds received in connection with the divestiture of a non-core asset. 
  • The deal consideration of $6.23 per share in cash has an implied enterprise value of approximately $149 million.
  • The FDA approved La Jolla's lead product, Giapreza in December 2017 to increase blood pressure in adults with septic or other distributive shocks. 
  • La Jolla's second asset, Xerava (eravacycline), was approved by the FDA in August 2018 for complicated intra-abdominal infections.
  • This acquisition strengthens Innoviva's portfolio in infectious diseases, anchored by the company's recent purchase of Entasis Therapeutics Holdings Inc.
  • Price Action: LJPC shares are up 81.4% at $6.15 premarket on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechM&ANewsPenny StocksHealth CareSmall CapMoversTrading IdeasGeneralBiotechnologyBriefsHealth Carewhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!